Ticagrelor is a BCS class IV drug that inhibits platelet action by reversibly binding to the
P2Y12 receptor. One of the major challenges faced by the class IV (low solubility, low …

The aim of this study was to increase the solubility and enhancement of dissolution rate of
poorly water-soluble drug ticagrelor this was done through formulating and evaluate …

DESIGN, OPTIMIZATION, AND CHARACTERIZATION OF A NOVEL AMORPHOUS SOLID
DISPERSION FORMULATION FOR ENHANCEMENT OF SOLUBILITY AND D Page 1 DESIGN …

The aim of the study was to develop a formulation of Ticagrelor 90 mg tablets that is
equivalent to the reference product using similar excipients to match the in-vitro dissolution …

The aim of this study is to improve the bioavailability of ticagrelor, BCS class 4 drug, using
solid dispersion technique, and to evaluate the potential of ticagrelor loaded-solid …

Objective: The goal of this study was to formulate ticagrelor tablets with enhanced
dissolution rate using cogrinding technique. However, it belongs to the biopharmaceutical …

The objective of this study was to develop a novel ticagrelor (TC) solid dispersion-loaded
tablet with enhanced solubility. Numerous polymers and surfactant were screened, and then …

Ticagrelor (TCG) is a Biopharmaceutics Classification System class IV drug with low
solubility and permeability. The purpose of the present study was to develop a stable …

Ticagrelor (TG) suffers from low peroral bioabsorption (36%) due to P-gp efflux and poor
solubility (10 µg/mL). TG solid dispersion adsorbates (TG-SDAs) were formulated using an …

Background: Ticagrelor (TGR), being an antiplatelet agent, belongs to BCS class IV drug
with low solubility and permeability that undergoes first-pass metabolism, leading to reduced …